Pricing

Foghorn Therapeutics Inc (FHTX)

followers ·
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Adrian Gottschalk
Employees: 120
Web site: foghorntx.com
500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
617-586-3100
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available